investorscraft@gmail.com

Intrinsic value of Glaukos Corporation (GKOS)

Previous Close$52.98
Intrinsic Value
Upside potential
Previous Close
$52.98

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh25.25 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %30.7NaN
Revenue, $294NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m327NaN
Operating income, $m-33NaN
EBITDA, $m2NaN
Interest expense (income), $mNaN
Earnings before tax, $m-49NaN
Tax expense, $m0NaN
Net income, $m-50NaN

BALANCE SHEET

Cash and short-term investments, $m414NaN
Total assets, $m1129NaN
Adjusted assets (=assets-cash), $m715NaN
Average production assets, $m532NaN
Working capital, $m423NaN
Total debt, $m383NaN
Total liabilities, $m542NaN
Total equity, $m587NaN
Debt-to-equity ratio0.652NaN
Adjusted equity ratio0.243NaN

CASH FLOW

Net income, $m-50NaN
Depreciation, amort., depletion, $m34NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m25NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-48NaN
Free cash flow, $m72NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m423
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount